TITLE

Prothrombin Mutation Conveying Antithrombin Resistance

AUTHOR(S)
Lotta, Luca A.; Martinelli, Ida; Peyvand, Flora; Simioni, Paolo; Campello, Elena; Spiezia, Luca; Matsushita, Tadashi; Saito, Hidehiko; Kojima, Tetsuhito
PUB. DATE
September 2012
SOURCE
New England Journal of Medicine;9/13/2012, Vol. 367 Issue 11, p1069
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
Letters to the editor are presented in response to the article "Thrombosis From a Prothrombin Mutation Conveying Antithrombin Resistance," by Y. Miyawaki et al in the 2012 issue, along with the reply of the authors of the article.
ACCESSION #
79820621

 

Related Articles

  • Visual compatibility of bivalirudin with selected drugs. Hartmann, Christian A.; Faria, Claudio E.; Mago, Kabeer // American Journal of Health-System Pharmacy;9/1/2004, Vol. 61 Issue 17, p1774 

    Presents a letter to the editor about the visual compatibility of bivalirudin thrombin inhibitor with selected drugs.

  • Rescuing COX-2 Inhibitors From the Waste Bin. Albini, Adriana; Noonan, Douglas M. // JNCI: Journal of the National Cancer Institute;6/1/2005, Vol. 97 Issue 11, p859 

    Presents a letter to the editor to suggest the combination of cyclooxygenase-2-specific inhibitors with anticoagulant, antithrombic agents that lack gastric side effects in order to compensate for the increased risk of potentially fatal cardiovascular complications.

  • Pharmacology and therapeutic applications of hirudin, an new anticoagulant. Glusa, Erika // Kidney International Supplement;Feb98, Issue 64, pS-54 

    Examines the pharmacology and therapeutic applications of hirudin, used for anticoagulant. Functions of hirudin as the most potent direct inhibitor of thrombin; Monitoring on the hirudin effects; Clinical aspects of hirudin therapy.

  • Bias in AJHP supplements. Kruse, Michael W.; Lee, Jeremy J. // American Journal of Health-System Pharmacy;12/15/2008, Vol. 65 Issue 24, p2328 

    A letter to the editor is presented in response to two articles in the previous issues including "Questionable conclusions about epoetin alfa" by M. W. Kruse and colleagues in the 2008 issue, and "Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary...

  • Cerebral Vein Thrombosis and Lupus Anticoagulant Antibodies. Marietta, Marco; Bertesi, Marcello; Simoni, Luisa; Castelli, Ilaria; Cappi, Cinzia; Torelli, Giuseppe // Clinical & Applied Thrombosis/Hemostasis;Jul2001, Vol. 7 Issue 3, p238 

    A letter to the editor is presented regarding a case of an atypical relapse of venous thromboembolism after withdrawal of oral anticoagulant therapy in a young woman carrying an antiphospholipid antibodies syndrome.

  • Ticlopidine and Thrombotic Thrombocytopenic Purpura. Kupfer, Yizhak; Tessler, Sidney // New England Journal of Medicine;10/23/97, Vol. 337 Issue 17, p1245 

    A letter to the editor is presented regarding "Ticlopidine and Thrombotic Thrombocytopenic Purpura," by Yizhak Kupfer and Sidney Tessler.

  • Anticoagulation for Idiopathic Deep-Vein Thrombosis. K√©vorkian, Jean-Philippe; Soria, Claudine // New England Journal of Medicine;12/20/2001, Vol. 345 Issue 25, p1852 

    A letter to the editor is presented in response to the article "Three Months Versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis," by G. Agnelli and colleagues in the July 19, 2001 issue.

  • Anticoagulation for Idiopathic Deep-Vein Thrombosis. Agnelli, Giancarlo; Prandoni, Paolo; Santamaria, Gabriella // New England Journal of Medicine;12/20/2001, Vol. 345 Issue 25, p1852 

    A response by Giancarlo Agnelli and colleagues to a letter to the editor about their article "Three Months Versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis" in the July 19, 2001 issue is presented.

  • Warfarin or Aspirin for Recurrent Ischemic Stroke. Powers, William J. // New England Journal of Medicine;4/11/2002, Vol. 346 Issue 15, p1169 

    A response from William J. Powers to several letters to the editor about his article on oral anticoagulant therapy for the prevention of stroke is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics